Table 3 Concordant p53 mutation and p53 IHC staining by demographic and clinical characteristics
From: A population-based study of immunohistochemical detection of p53 alteration in bladder cancer
| Â | p53 mutation/persistent staining | p53 mutation/intensity | ||||
|---|---|---|---|---|---|---|
| Â | p53 wt/IHC <50% | p53 mutant/IHC>50% | OR (95% CI)a | p53 wt/IHC <3 | p53 mutant/IHC 3+ | OR (95% CI)a |
Characteristic | N (%) | N (%) | Â | N (%) | N (%) | Â |
Sex | Â | Â | Â | Â | Â | Â |
 Female | 22 (21.6) | 9 (39.1) | 1.0 (reference) | 54 (23.5) | 6 (37.5) | 1.0 (reference) |
 Male | 80 (78.4) | 14 (60.9) | 0.5 (0.2–1.6) | 176 (76.5) | 10 (62.5) | 0.4 (0.1–1.4) |
Age (year) | Â | Â | Â | Â | Â | Â |
 <55 | 18 (17.6) | 7 (30.4) | 1.0 (reference) | 44 (19.1) | 4 (25.0) | 1.0 (reference) |
 55–65 | 34 (33.3) | 3 (13.0) | 0.2 (0.0–0.9) | 78 (33.9) | 3 (18.8) | 0.4 (0.1–2.2) |
 >65 | 50 (49.0) | 13 (56.5) | 0.4 (0.1–1.5) | 108 (47.0) | 9 (56.2) | 0.5 (0.1–2.2) |
Stage | Â | Â | Â | Â | Â | Â |
 Noninvasive | 71 (70.3) | 10 (43.4) | 1.0 (reference) | 197 (86.0) | 4 (25.0) | 1.0 (reference) |
 Invasive | 30 (29.7) | 13 (56.5) | 1.5 (0.5–4.7) | 32 (14.0) | 12 (75.0) | 3.3 (0.8–13.0) |
Grade | Â | Â | Â | Â | Â | Â |
 G1 | 25 (24.8) | 2 (8.7) | 1.0 (reference) | 109 (47.6) | 0 | — |
 G2 | 41 (40.6) | 4 (17.4) | 1.4 (0.2–8.8) | 82 (35.8) | 2 (12.5) | 1.0 (reference) |
 G3 | 35 (34.7) | 17 (73.9) | 6.3 (1.0–38.6) | 38 (16.6) | 14 (87.5) | 9.0 (1.7–47.5) |
Disease group b | Â | Â | Â | Â | Â | Â |
 TaG1-2 | 57 (55.9) | 6 (26.1) | 1.0 (reference) | 178 (77.4) | 2 (12.5) | 1.0 (reference) |
 CIS | 1 (1.0) | 0 | — | 1 (0.4) | 0 | — |
 TaG3/T1 | 36 (35.3) | 10 (43.5) | 3.1 (0.9–9.9) | 42 (18.3) | 7 (43.7) | 17.6 (3.3–92.9) |
 T2 | 8 (7.8) | 7 (30.4) | 10.6 (2.5–45.5) | 9 (3.9) | 7 (43.7) | 77.4 (13.0–460.1) |
